StockNews.AI
CRMD
StockNews.AI
154 days

CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

1. CRMD will report Q4 and full year 2024 results on March 25, 2025. 2. DefenCath® was FDA approved and launched commercially in 2024. 3. Clinical studies for DefenCath in TPN and pediatric HD patients will start in 2025. 4. Ongoing commercialization efforts may enhance CRMD's market position significantly. 5. The corporate conference call may impact investor sentiment and stock performance.

3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results and ongoing clinical trials create positive market expectations. Similar patterns in biopharmaceutical firms have often led to price increases post-announcement.

How important is it?

The scheduled earnings and updates on product launches are significant metrics affecting CRMD's valuation. Stakeholders await these updates to gauge future performance and potential growth.

Why Short Term?

The conference call and financial results are immediate events that will influence short-term trading. Historical examples show that earnings reports can lead to rapid price movements.

Related Companies

ABCLMNKDNVS
March 18, 2025 08:30 ET  | Source: CorMedix, Inc. BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, March 25th @ 8:30am ETDomestic: 1-844-481-2557International: 1-412-317-0561Conference ID: 10197392Webcast: Webcast Link    About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com. Investor Contact:Dan FerryManaging DirectorLifeSci Advisorsdaniel@lifesciadvisors.com (617) 430-7576

Related News